Sorafenib and TRC105 in Hepatocellular Cancer




Study location

Global sites currently include Australia, Belgium, Brazil, Canada, Czech Republic, Estonia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Lithuania, Poland, Romania, Russian Federation, Spain, United Kingdom, and the United States.

About Napabucasin

Napabucasin is an orally administered investigational agent designed to inhibit cancer stem cell pathways by targeting STAT3.

Preliminary results of napabucasin plus paclitaxel as second-line therapy in patents with advanced gastric and GEJ adenocarcinoma were published as a poster at the ASCO Annual Meeting 2015. Click here to download the poster. Napabucasin is an investigational agent and not approved by the US FDA.

Learn more about the BRIGHTER trial at (NCT02178956)

Boston Biomedical is a biopharmaceutical company focused on the research and development of novel cancer therapeutics targeting cancer stem cell pathways.

Study locations noted above are as of May 2016